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Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based
therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected
number of unexplained deaths were reported with front-line ibrutinib in a patient population
aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.
Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib
was associated with a greater mortality in older patients outside of a clinical trial setting. This
multicenter analysis was performed by investigators at 20 academic and community
practices.
Results: Amongst the 391 patients included, there was no correlation between age and
response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).
Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in
an older population. Patients should be educated regarding the potential complications
related to ibrutinib and symptoms of concern to report.
Keywords: CLL, ibrutinib, elderly

Introduction
Recently published cooperative group studies, Alliance A041202 and ECOG E1912,
have established the role of ibrutinib over chemoimmunotherapy for the front-line
treatment of chronic lymphocytic leukemia (CLL).1,2 Notably, Alliance A041202,
which evaluated patients ≥65-years-old receiving ibrutinib with or without rituximab
or the combination of bendamustine and rituximab (BR), reported a higher than
expected number of deaths in both of the ibrutinib-containing arms.1 Ten unex
plained/unknown deaths occurred among the 361 patients receiving ibrutinib; whereas
1 such event occurred in the BR arm (n=176). These data were in contrast to ECOG
E1912 in which ibrutinib plus rituximab was associated with an improvement in
overall survival (OS) compared to FCR (fludarabine, cyclophosphamide, rituximab)
in patients less than 70 years of age.2 Together, these data suggest ibrutinib may be
associated with significant adverse events (AE) and greater mortality in an elderly
CLL population. We sought to investigate this hypothesis in previously untreated
patients who received commercially available ibrutinib as initial therapy for CLL.

Methods
This multicenter retrospective analysis was performed by investigators at 20 academic
and community practices. The study was approved by the institutional review board at
1
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each participating institution (Supplementary Materials).
Informed consent was waived because the research involved
no more than minimal risk to the patient. In compliance with
the Declaration of Helsinki, patient confidentiality was main
tained through de-identified data collection practices.
Patients were considered eligible for inclusion if they
received ibrutinib for the front-line treatment of CLL through
commercial sources. Medical chart review via diagnostic
codes was performed to identify all CLL patients at each
institution. Investigators utilized chart review, electronic
medical records, and related databases to obtain required
information. Patient demographics, prognostic markers, ibru
tinib dosing administration, and clinical outcomes data were
collected. The International Workshop on Chronic
Lymphocytic Leukemia (iwCLL, 2008) criteria were used
to define response and progression of disease.3
The primary endpoint was OS as determined by the
Kaplan Meier method.4 OS was defined as time from initia
tion of ibrutinib to death. Comparisons of survival were
made using COX regression analyses.5,6 All other compar
ison analyses were descriptive. Early deaths were defined as
a death from any cause occurring within 12 months of
ibrutinib treatment initiation. Secondary endpoints included
response rates, progression-free survival (PFS), discontinua
tion rates, and reasons for discontinuation. PFS was defined
as time from ibrutinib initiation to progression or death from
any cause. Patients were otherwise censored at the time of
last follow-up. Statistical analyses were performed using
STATA 10.1 (Stata Statistical Software: Release 10, 2007;
StataCorp LP, College Station, TX). All tests were two-sided
at the 5% level.

Results
Of the 391 patients identified, 59% were 65 years or older
(≥65 YO). The median age at initiation of ibrutinib was 63
years (range 36–96). Patient characteristics are detailed in
Table 1. Poor risk prognostic features were similar in
patients stratified by age at start of ibrutinib (≥65 YO
and <65 YO cohorts, respectively): del 17p (29%, 30%),
TP53 mutation (21%, 19%), IGHV unmutated (71%,
64%), and complex karyotype (25%, 21%).
The median time from diagnosis to initiation of ibrutinib
was 35 months for patients ≥65 YO and 25 months for those
<65 YO. Eleven percent of older patients were initiated on
a lower than standard dose of ibrutinib (420 mg daily) in
contrast to 2% of younger patients (p=0.02). In older patients,
20% required dose reduction compared to 13% of younger
patients (p=0.07). Dose interruptions occurred in 46% of older

2
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Table 1 Patient Characteristics

Sex
M
F

<65 YO (n=160)

≥65 YO (n=231)

63%

62%

37%

38%

90%
10%

94%
6%

(n=158)
70%

(n=211)
71%

30%

29%

Race
Caucasian
Other
del 17p
Absent
Present
TP53 mutation

(n=102)

(n=117)

Absent

81%

79%

Present

19%

21%

(n=158)

(n=209)

79%
21%

86%
14%

(n=122)
79%

(n=157)
75%

21%

25%

del 11q
Absent
Present
Complex Karyotype
Absent
Present
IgVH

(n=102)

(n=119)

Unmutated

64%

71%

Mutated

36%

29%

and 36% of younger patients (p=0.04); the median duration of
dose interruption was 13 and 10 days, respectively (p=0.49).
Ibrutinib discontinuation occurred in similar frequency for
older and younger patients (25%, 22%). Intolerance was the
most common reason for discontinuation in both age groups
(n= 36 and 20, respectively), followed by CLL progression (n=
6, 6), and Richter’s transformation (n= 5, 4).
Investigator assessed overall and complete response rates
for ibrutinib were 79% and 15% in patients ≥65 YO and 85%
and 20% in those <65 YO. There was no difference in PFS
based on age (HR 1.13, p =0.69), Figure 1. At a median follow
up of 13.8 months (range 1–76 months), a total of 26 deaths
were observed. There was a higher proportion of deaths in the
older cohort (8.7% vs 3.8%, 20 deaths vs 6 deaths), though
difference in OS did not reach statistical significance (HR 2.1,
p=0.097). Figure 1. The number of early deaths, defined as
occurring within the first 12 months of therapy, was 13 in
patients ≥65 YO compared to 4 in patients <65 YO, p=0.3.

Conclusion
In this cohort of nearly 400 patients who received single
agent ibrutinib for the front-line treatment of CLL, age did
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Figure 1 Survival by age.

not correlate with response rates, progression-free survi
val, or overall survival. Nevertheless, a greater than twofold increase in death was noted in patients ≥65-years-old
compared to the younger cohort. Similar to the data
reported in the Alliance A041202 study, where the major
ity of unexplained deaths with ibrutinib occurred within
the first two years of treatment, early deaths in our analysis
appeared to occur more frequently in the older patient
population.1 These data support our initial hypothesis
that ibrutinib may be associated with a greater early mor
tality in an older CLL population.
In this analysis, nearly 50% of the older population
required dose interruptions and 20% required dose reduc
tions suggesting issues with drug tolerability related to
AEs. Furthermore, it appears that practitioners anticipated
an increase in AEs in the older population as they more
frequently prescribed lower than standard doses of ibruti
nib at initiation of therapy. Alternatively, this may repre
sent decreased experience with the drug in the early days
of approval. Despite these findings, the incidence of
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ibrutinib discontinuation was relatively comparable
between the different age groups. Additionally, intolerance
to ibrutinib remained the most common reason for discon
tinuation of therapy in all patients.
When comparing the grade 3–5 adverse events that
occurred with ibrutinib in the older Alliance A041202
and younger ECOG E1912 populations, the most notable
differences are the increased rates of cardiovascular toxi
city, specifically atrial fibrillation (9% vs 3%) and hyper
tension (29% vs 7%).1,2 A recent retrospective analysis of
562 patients receiving ibrutinib at the Ohio State
University also noted a marked incidence of new hyper
tension of 72%.7 Major cardiac events were noted in 17%
of patients and occurred more frequently in those with new
or worsening hypertension (19%). In a separate aggregated
data set of over 1000 patients receiving ibrutinib, 10
events of sudden death or cardiac arrest were identified.8
The HELIOS study of BR with or without ibrutinib was
included in this analysis; 7 events of ≥ grade 3 ventricular
arrhythmia, cardiac arrests, and sudden deaths were found
in the ibrutinib-containing arm compared to 0 with BR
alone.9 The higher incidence of these toxicities raises
suspicion for a cardiac event as a potential etiology for
the unexplained, early deaths noted in both Alliance
A041202 and this analysis; however, investigators were
unable to confirm this impression. It is also noted that
early death is not necessarily the same as sudden death.
Unfortunately, a critical limitation of our analysis is that
the individual causes of death were not captured uniformly
as part of this retrospective data review, nor were the past
cardiac histories. We were unable to identify which, if any,
adverse events occurred in patients who experienced an
early death or assign attribution to drug. However, given
the marked efficacy of ibrutinib and the ability of patients
to be effectively salvaged after progression, one may
assume that toxicity may be a key contributing factor.
Given the quickly evolving treatment landscape for
CLL, one of the more complicated decisions oncologists
will face is determining the most appropriate novel ther
apeutic for their individual patient. Ibrutinib is certainly
a highly effective therapy for patients of all ages, ensuring
a lengthy PFS and OS in elderly patients with high-risk
disease. However, as the majority of patients with CLL are
elderly and many have comorbidities, ensuring tolerability
is crucial. While our data are hypothesis generating only,
these findings in combination with those of Woyach et al
suggest close monitoring of elderly patients treated with
ibrutinib is warranted for toxicity, particularly in the first
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12 months of therapy.1 In addition, patients should be
educated regarding the potential complications related to
treatment and symptoms of concern to report.
Fortunately, a number of effective agents have or will
become available to patients in the near future. The
CLL-14 study of venetoclax and obinutuzumab recently
secured the B-cell lymphoma (BCL)-2 inhibitor a role in
the front-line setting.10 The safety of venetoclax in an
elderly population with comorbidities, including decreased
renal function, was demonstrated in this study. However, 5
fatal adverse events were noted during treatment, primarily
due to infection, as well as 4 fatal infection events which
occurred after completion of venetoclax. The incidence of
severe neutropenia was 53% in this study, highlighting the
importance in supporting and monitoring patients appro
priately both during and after therapy. Additionally, there
are second-generation Bruton tyrosine kinase (BTK) inhi
bitors in development, including acalabrutinib and zanu
brutinib, which may be associated with less atrial
fibrillation.11,12 Their relative risk of early deaths will be
forthcoming with the results of Phase III trials. The com
bination of a BTK inhibitor and a BCL-2 inhibitor has also
demonstrated remarkable efficacy with a shorter required
treatment duration and thus less time for drug exposure.13
Whether fixed duration combination strategies will result
in less toxicity or early deaths is unknown. Moving for
ward, although the correlation between age and survival
was not shown to be statistically significant, we do feel
a greater effort must be focused on understanding whether
the cause of early mortality in older patients receiving
ibrutinib is related to the drug or the patient; additionally,
how best to mitigate this problem which may limit the use
of this highly effective agent.
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